How would you measure the success of Moderna's mRNA-1273 COVID-19 vaccine?

Introduction

Measuring the success of Moderna's mRNA-1273 COVID-19 vaccine requires a comprehensive approach that considers multiple stakeholders and complex factors. To address this product success metrics challenge, I'll follow a structured framework covering core metrics, supporting indicators, and risk factors while considering all key stakeholders.

Step 1

Product Context

Moderna's mRNA-1273 is a novel vaccine developed to prevent COVID-19 infection. It uses messenger RNA (mRNA) technology to instruct cells to produce a harmless piece of the virus's spike protein, triggering an immune response.

Key stakeholders include:

• Patients: Seeking protection from COVID-19
• Healthcare providers: Administering the vaccine and managing patient care
• Governments: Procuring and distributing vaccines to populations
• Regulatory bodies: Ensuring vaccine safety and efficacy
• Moderna: Developing, manufacturing, and distributing the vaccine

User flow:

1. Patient receives information about vaccine availability
2. Patient schedules appointment and receives first dose
3. Patient returns for second dose after prescribed interval
4. Patient may receive booster doses as recommended

The mRNA-1273 vaccine is a crucial part of Moderna's strategy to establish itself as a leader in mRNA therapeutics. It competes with other COVID-19 vaccines, including Pfizer-BioNTech's mRNA vaccine and more traditional vaccines like Johnson & Johnson's adenovirus-based vaccine.

Product Lifecycle Stage: The vaccine is in the growth stage, with ongoing research for new variants and potential combination vaccines.

Physical Product Considerations:

• Distribution channels: Requires ultra-cold chain logistics
• Shelf-life: Limited, requiring careful inventory management
• Sales model: Primarily B2G (Business to Government) with some B2B (Business to Business) for private healthcare providers